Elizabeth Ormondroyd

liz ormondroyd headshot
Associate Professor
Radcliffe Department of Medicine (Division of Cardiovascular Medicine), University of Oxford

 

Background and research interests:

 

Liz's research focuses on understanding the impacts of developments in genomic technology on patients, families and society.  In the CureHeart project, she is developing research to understand the perspectives of people living with cardiomyopathy, and of current and future treatments.  Findings will inform which patients might most benefit from genetic therapies, development of patient-preferred therapy strategies, and incorporation of patient-valued outcomes in trial design.  She will also lead work to identify and understand ethical issues that might arise from the CureHeart project.

 

Liz completed her PhD at King's College, London.  She is also a registered Genetic Counsellor, with genetic counselling experence with patients and families with inherited heart conditions.

 

 

Selected Publications:

 

  1. Secondary (additional) findings from the 100,000 Genomes Project: Disease manifestation, health care outcomes, and costs of disclosure. Nolan et al. (2024) Genetics in Medicine 
  2. Additional findings from the 100,000 Genomes Project: A qualitative study of recipient perspectives Nolan J, Forrest j & Ormondroyd E. (2024). Genetics in Medicine
  3. Direct-to-consumer genetic tests providing health risk information: A systematic review of consequences for consumers and health services.  Nolan J & Ormondroyd E (2023).  Clinical Genetics
  4. A practical checklist for return of results from genomic research in the European context.  Vears DF et al. (2023).  European Journal of Human Genetics
  5. Public and patient involvement in research to support genome services development in the UK. Hunter A et al. (2023).  Journal of Translational Genetics and Genomics 7:17-26
  6. Genomic health data generation in the UK: a 360 view.  Ormondroyd E et al. (2021).  European Journal of Human Genetics
  7. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity.  Harper AR et al. (2021). Nat Genet 53: 135-142
  8. Taking it to the Bank: The Ethical Management of Individual Findings Arising in Secondary Research.  Graham M et al. (2020).  Journal of Medical Ethics
  9. Secondary findings in inherited heart condititons: a genotype-first feasibility study to assess phenotype, behaviourial and psychosocial outcomes.  Ormondroyd E et al. (2020). Eur J Hum Genet 28: 1486 - 1496
  10. From Genotype to Phenotype.  Clinical Assessment and Participant Perspective of a Secondary Genomic Finding Associated with Long QT Syndrome.  Mackley M et al. (2018).  Circ Genom Precis Med, 11
  11. Views of rare disease participants in a UK whole-genome sequencing study towards secondary findings: a qualitative study.  Mackley MP et al. (2018). Eur J Hum Genet 26: 652-659
  12. "Not pathogenic until proven otherwise": perspectives of UK clinical genomics professionals toward secondary findings in context of a Genomic Medicine Multidisciplinary Team and the 100,000 Genomes Project.  Ormondroyd E et al. (2018) 20: 320-328
  13. Exploring the potential duty of care in clinical genomics under UK law.  Mitchell C et al. (2017). Med Law Int 17: 158-182
  14. Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies.  Mackley MP et al. (2017). Genet Med 19: 283-293
  15. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications.  Ormondroyd E et al. (2014) Eur J Hum Genet 22:88-93